

1 **Characteristics and outcomes of patients treated with sotrovimab** 2 **to prevent progression to severe COVID-19 in Belgium**

3 Myriam Drysdale^{1†*}, Thor Hautekiet^{2†}, Moushmi Singh¹, Joris Hautekiet^{3‡}, Linda
4 Ludikhuyze³, Vishal Patel^{1‡}, Daniel C Gibbons¹, Dorothee De Roeck⁴, Kirsten Colpaert⁵,
5 Emily J Lloyd¹, Eva Van Braeckel^{2,6}

6 ¹GSK, Brentford, UK

7 ²Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium

8 ³IQVIA Belux, Zaventem, Belgium

9 ⁴GSK, Wavre, Belgium

10 ⁵Department of Intensive Care, Ghent University Hospital, Ghent, Belgium

11 ⁶Respiratory Infection and Defense Lab, Department of Internal Medicine and Pediatrics,
12 Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium

13

14

15 [†]Myriam Drysdale and Thor Hautekiet contributed equally to the manuscript.

16 [‡]Affiliation correct at time of study.

17

18 **Correspondence:**

19 *Myriam Drysdale

20 myriam.g.drysdale@gsk.com

21

22 **ORCID IDs:**

23 Myriam Drysdale: 0000-0002-8994-2816

24 Daniel C Gibbons: 0000-0002-3769-9535

25 Eva Van Braeckel: 0000-0002-7242-0747

26

27

27 **Abstract**

28 **Background** Sotrovimab, a dual-action, engineered human monoclonal antibody, has been
29 demonstrated to significantly reduce the risk of hospitalization and death in high-risk patients
30 with COVID-19. Here, we describe the real-world use of, and outcomes from, sotrovimab

31 treatment in Belgium during the Delta and Omicron waves among patients with COVID-19 at
32 high risk of developing severe disease.

33 **Methods** This was a multicentric, single-arm observational cohort study of non-hospitalized
34 patients receiving outpatient sotrovimab treatment between 1 November 2021 and 2 August
35 2022. We performed a retrospective analysis of hospital, pharmacy and administrative data
36 from nine hospitals in Belgium. The primary outcomes were all-cause and COVID-19-related
37 hospitalizations and all-cause deaths during the 29-day acute follow-up period from first
38 administration of sotrovimab.

39 **Results** A total of 634 patients were included in the analysis (63.4% aged <65 years; 50.3%
40 male). A high proportion (67.7%; $n = 429/634$) of patients were immunocompromised, with
41 36.9% ($n = 234/634$) actively treated for malignancy. During the 29-day acute period, 12.5%
42 ($n = 79/634$) of sotrovimab-treated patients were hospitalized due to any cause (median
43 duration 4 days; median time to hospitalization 14 days) and 1.1% ($n = 7/634$) died due to
44 any cause. In total, 0.8% ($n = 5/634$) of patients were admitted to an intensive care unit
45 (ICU). COVID-19-related hospitalization was experienced by 2.5% ($n = 16/634$) of patients
46 (median duration 10 days; median time to hospitalization 10.5 days), with 0.5% ($n = 3/634$)
47 of patients admitted to an ICU. COVID-19-related hospitalization was experienced by 6.3%
48 ($n = 3/48$) of patients during Delta predominance (04/11/2021–23/12/2021), 6.3% ($n = 1/16$)
49 of patients during Delta/BA.1 codominance (24/12/2021–01/01/2022), 1.4% ($n = 3/218$) of
50 patients during BA.1 predominance (02/01/2022–09/02/2022), 2.1% ($n = 2/97$) of patients
51 during BA.1/BA.2 codominance (10/02/2022–07/03/2022) and 2.7% ($n = 7/255$) of patients
52 during BA.2/BA.5 codominance (08/03/2022–02/08/2022).

53 **Conclusions** This observational study demonstrated consistently low rates of COVID-19-
54 related hospitalizations and all-cause deaths in sotrovimab-treated patients during the
55 Omicron subvariant periods in Belgium, despite over two-thirds of the study population being

56 immunocompromised. Comparative effectiveness studies are warranted to confirm
57 sotrovimab effectiveness in highly immunocompromised patients with COVID-19.

58 **Keywords:** COVID-19; monoclonal antibody; Omicron BA.1; Omicron BA.2; SARS-CoV-2;
59 sotrovimab

60 **Background**

61 Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory
62 syndrome coronavirus 2 (SARS-CoV-2); the rapid global spread of SARS-CoV-2 resulted in
63 the declaration of a pandemic by the World Health Organization in March 2020 [1]. Globally,
64 as of September 2023, there have been over 770 million confirmed cases of COVID-19,
65 including nearly 7 million deaths [2]. In Belgium, almost 158,000 hospitalizations and 34,000
66 deaths have been attributed to COVID-19 during the same period [2, 3].

67 Older individuals or those with immunosuppression, cancer, obesity, diabetes, or
68 chronic kidney, lung, liver or cardiovascular disease are known to be at higher risk of
69 developing severe COVID-19, which may result in hospitalization or death [4-6].

70 Sotrovimab is a dual-action, engineered human immunoglobulin G1 κ monoclonal
71 antibody (mAb) derived from the parental mAb S309, a potent neutralising mAb directed
72 against the spike protein of SARS-CoV-2 [7-10]. Sotrovimab (administered as a single
73 500 mg intravenous dose) was shown in COMET-ICE, a randomized clinical trial, to
74 significantly reduce the risk of all-cause >24-hour hospitalization or death compared with
75 placebo in high-risk patients with COVID-19 [11].

76 As a result of positive findings from COMET-ICE, sotrovimab received marketing
77 authorization from the European Medicines Agency (EMA) in December 2021 for use in
78 adults and adolescents (aged ≥ 12 years and weighing ≥ 40 kg) with COVID-19 who do not
79 require oxygen supplementation and are at increased risk of progressing to severe

80 COVID-19 [12]. In Belgium, use of sotrovimab began prior to EMA approval as a result of a
81 procurement framework contract issued by the European Commission in July 2021 that
82 enabled participating European Union member states, including Belgium, to purchase
83 sotrovimab prior to its marketing authorization [13, 14]. At the time of the study, mAbs
84 (including sotrovimab) were recommended for the treatment of mild-to-moderate COVID-19
85 among patients in Belgium at high risk of complications, following authorization by a
86 multidisciplinary team including at least one infectious disease physician and one
87 immunologist [15]. Due to limited supplies of mAbs, immunocompromised patients were
88 considered the highest priority for mAb treatment [15].

89 Sotrovimab has been granted marketing authorization in the European Union,
90 Norway, Iceland [16], Australia (conditional) [17], United Kingdom (conditional) [18], Saudi
91 Arabia (conditional) [19] and Switzerland (conditional) [19]. In Japan, a Special Approval for
92 Emergency designation has been granted [20]. Since the approval of sotrovimab, waves of
93 new SARS-CoV-2 variants of concern have emerged, including the Delta variant and the
94 Omicron BA.1, BA.2 and BA.5 subvariants; the latter became dominant in Belgium in June
95 2022 [21-23]. *In vitro* neutralization studies have demonstrated a moderate fold shift in
96 activity of sotrovimab against Omicron BA.2 relative to wild-type SARS-CoV-2 (16-fold
97 change in EC_{50} relative to wild-type) [24]. A similar reduction in activity was reported for
98 sotrovimab against BA.5 (22.6-fold change in EC_{50} relative to wild-type) [24]. Consequently,
99 on 28 April 2022, the Federal Agency for Medicines and Health Products regulatory body in
100 Belgium took the decision to no longer recommend the use of sotrovimab [25], although use
101 continued among very-high-risk and/or immunocompromised patients.

102 In the absence of a clinical trial conducted during the Omicron predominance period,
103 it remains uncertain how *in vitro* antibody neutralization activity correlates with clinical
104 effectiveness, especially for dual-action antibodies like sotrovimab that have potent effector
105 function, including antibody-dependent cellular cytotoxicity and antibody-dependent cellular
106 phagocytosis [10, 26, 27]. Real-world studies are an important source of data with which to

107 assess clinical outcomes in patients treated with sotrovimab within the evolving variant
108 landscape.

109 Here, we describe the real-world use of, and outcomes from, sotrovimab treatment
110 for the management of patients with COVID-19 at high-risk of developing severe disease
111 between 1 November 2021 and 2 August 2022 in Belgium, when the Delta variant and
112 Omicron BA.1, BA.2 and BA.5 subvariants were predominant.

113 **Methods**

114 **Study design and data source**

115 In this single-arm observational cohort study, data were collected retrospectively from nine
116 centres (including two university hospitals) located in Flanders, Brussels and Wallonia that
117 administered sotrovimab in an outpatient setting from 1 November 2021 up to and including
118 2 August 2022. Patient-level data were collected and aggregated from three main sources:
119 1) registered administrative, medical and nursing data, which are fully structured and
120 standardized across all hospitals and therefore require no specific technology to be
121 implemented for data retrieval; 2) structured and standardized hospital pharmacy or
122 invoicing data using predefined Anatomical Therapeutic Chemical (ATC) codes to capture
123 the date of sotrovimab administration; 3) administrative data regarding hospital admission
124 and transfer.

125 The index date (Day 1) was defined as the date of first treatment administration with
126 sotrovimab. The baseline period was defined as the 1 year prior to index for assessment of
127 prior comorbidities. All-cause and COVID-19-related outcomes were reported during the
128 acute period, defined as the 29-day follow-up period starting on the index date. End of
129 follow-up was defined as either the end of the acute period, death or the study end (31
130 August 2022), whichever occurred first.

131 This study complies with all applicable laws regarding subject privacy. No direct
132 subject contact or primary collection of individual human subject data occurred. Study results
133 were in tabular form and were aggregate analyses that omitted subject identification;
134 therefore, informed consent was not required. Ethics committee approval was obtained from
135 each of the participating centres, with the exception of AZ Maria Middelaes, AZ Groeninge
136 and Jan Yperman where approval was provided by a data access committee.

137 **Study population**

138 Non-hospitalized patients infected with SARS-CoV-2 were eligible for inclusion if they were
139 aged ≥ 12 years on the index date and received outpatient treatment with sotrovimab for the
140 first time during the study period.

141 Patients were excluded if they received sotrovimab in an inpatient setting and/or
142 received remdesivir as an early treatment in an outpatient setting during the acute period.
143 However, in three of the study centres, patients routinely stayed in hospital overnight after
144 sotrovimab administration for logistical (i.e. for monitoring post treatment administration)
145 rather than medical reasons; therefore, the exclusion criteria were adapted for these centres
146 to include patients discharged the day after sotrovimab administration.

147 **Study outcomes**

148 Patient demographics and clinical characteristics were collected based on the presence of
149 selected International Classification of Disease version 10 (ICD-10) and ATC codes (Tables
150 S1–S3) during any hospital visit that occurred in the 12 months prior to the index date.
151 These included age, sex, and comorbidities and risk factors that may predispose patients to
152 severe COVID-19 outcomes, as follows: immunocompromised status (human
153 immunodeficiency virus infection/acquired immunodeficiency syndrome, treatment for solid
154 tumours, haematological malignancy, solid organ or haematopoietic stem cell
155 transplantation, primary immune deficiency, receiving immunosuppressive drugs [see **Table**
156 **S1**], sickle-cell anaemia, major thalassaemia, asplenia); other risk factors or comorbidities of

157 interest (age ≥ 65 years old, obesity, type 1 or type 2 diabetes mellitus, chronic lung disease
158 including asthma and cystic fibrosis, cardiovascular disease including uncontrolled
159 hypertension, chronic kidney disease [CKD; estimated glomerular filtration rate < 30 ml/min]
160 including treatment via haemodialysis, chronic liver disease [Child–Pugh B or C], chronic
161 neurological disease). These comorbidities and risk factors for severe COVID-19 aligned
162 with those reported by the Scientific Institute for Public Health of the Federal Belgian State
163 (Sciensano) and the US Centers for Disease Control and Prevention [5, 6].

164 The clinical outcomes of this study included the number and proportion of all-cause
165 and COVID-19-related hospitalizations and all-cause deaths during the acute period (29
166 days after the index date). COVID-19-related hospitalizations were defined as having the
167 following ICD-10 codes registered as the verified admission diagnosis: B34.2, B97.2 or
168 U07.1 (**Table S2**). In a *post hoc* analysis, cause of death data were collected for patients at
169 Ghent University Hospital and the proportion of COVID-19-related deaths was determined;
170 only all-cause deaths are reported for the other centres.

171 The number and proportion of all-cause and COVID-19-related hospitalizations and
172 all-cause deaths among sotrovimab-treated patients were reported for the overall population
173 and stratified by week and month, as well by the period of SARS-CoV-2 variant
174 predominance in Belgium [28], as follows: Delta predominance period, 4 November 2021–
175 23 December 2021; Delta/BA.1 codominance period, 24 December 2021–1 January 2022;
176 BA.1 predominance period, 2 January 2022–9 February 2022; BA.1/BA.2 codominance
177 period, 10 February 2022–7 March 2022; BA.2/BA.5 codominance period, 8 March 2022–2
178 August 2022 (Fig. 1). The study design did not enable collection of polymerase chain
179 reaction results in order to identify the SARS-CoV-2 variant strains that patients were
180 infected with. Rather, to map the 29-day outcomes with the circulating variants, we used a
181 proxy based on the most prevalent strains circulating in Belgium per week, as provided by
182 Sciensano [28].

183 In addition, the length of stay (defined as number of hospitalization days), time to
184 hospitalization after the index date, number and proportion of patients admitted to intensive
185 care, and the number and proportion of patients receiving non-invasive or mechanical
186 ventilation during all-cause or COVID-19-related hospitalization were captured during the
187 acute period.

188 In an exploratory analysis, all-cause and COVID-19-related new hospitalizations and
189 all-cause deaths reported during the post-acute period, defined as the period between Day
190 30 and Day 90 after the index date, were assessed. Data for the exploratory analysis could
191 only be collected for patients identified on or before 1 June 2022 to allow time for Day 30–90
192 follow-up to be completed before the end of the study period (31 August 2022).

193 **Data analysis**

194 Descriptive analyses were performed. For continuous variables, the mean, standard
195 deviation (SD), median and interquartile range (IQR) were calculated. Proportions were
196 calculated using the total number of eligible patients treated with sotrovimab as the
197 denominator, unless otherwise specified. The prevalence of hospitalization or death during
198 the respective SARS-CoV-2 variant predominance periods was calculated as the number of
199 patients who experienced that event during the variant predominance period divided by the
200 total number of sotrovimab-treated patients during that period multiplied by 100.

201 For post-acute 90-day outcomes, the proportions of hospitalizations (all-cause and
202 COVID-19-related) and deaths (all-cause) were calculated among the number of patients
203 treated with sotrovimab who were still alive at the beginning of the post-acute period and had
204 completed the 90-day follow-up.

205 Results

206 Patient identification and characteristics

207 Following application of the inclusion and exclusion criteria, 634 patients were included in
208 the study (**Table 1**). A total of 598 patients identified across the study centres had received
209 sotrovimab while already hospitalized and were excluded from the study. No patients
210 identified had received remdesivir as an outpatient during the acute COVID-19 infection
211 period.

212 **Table 1** Number of patients excluded and included per study centre (1 November 2021–2
213 August 2022)

Study centre	Number of patients identified as treated with sotrovimab	Non-eligible		Number of patients eligible for inclusion in study analysis
		Number of patients treated with sotrovimab in a hospitalized setting*	Number of patients treated with remdesivir during the acute COVID-19 infection period	
UZ Gent	650	272	0	378
Hôpital Erasme	119	70	0	49
AZ Damiaan	26	22	0	4
AZ Groeninge	58	27	0	31
AZ Jan Yperman	73	28	0	45
AZ Sint-Lucas	48	31	0	17
AZ Maria Middelaes	149	78	0	71
CHU Ambroise Paré	35	13	0	22
CHU Clinique Saint-Pierre	74	57	0	17
Total	1232	598	0	N = 634

214

215 *At AZ Sint-Lucas, CHU Clinique Saint-Pierre and CHU Ambroise Paré, patients routinely stayed in hospital
216 overnight after sotrovimab administration for logistical (i.e. for monitoring post treatment administration) rather
217 than medical reasons; therefore, the exclusion criteria were adapted for these centres to include patients
218 discharged the day after sotrovimab administration

219 **Table 2** presents the baseline demographic and clinical characteristics among
220 sotrovimab-treated patients included in the analysis. The patients were predominantly aged
221 <65 years (63.4%, $n = 402/634$), with more than one-third (38.6%, $n = 245/634$) of patients
222 aged 18–54 years. Half of the patients (50.3%, $n = 319/634$) were male, and 67.7% ($n =$
223 $429/634$) were immunocompromised and thus considered at high risk of developing COVID-
224 19 complications. Most of the immunocompromised patients had a malignancy and were
225 undergoing treatment with antineoplastic agents, endocrine therapies or immunostimulants
226 (36.9%, $n = 234/634$), or had primary immune deficiency (29.7%, $n = 188/634$) or a
227 haematological malignancy (25.4%, $n = 161/634$). With respect to the other risk factors and
228 comorbidities of interest (excluding age ≥ 65 years), cardiovascular disease (17.7%, $n =$
229 $112/634$), diabetes (12.3%, $n = 78/634$) and CKD (10.6%, $n = 67/634$) were the most
230 common.

231 **Table 2** Patient characteristics

Characteristic	Sotrovimab ($N = 634$)
Age group, years, n (%)	
12–17	23 (3.6)
18–54	245 (38.6)
55–64	134 (21.1)
65–74	140 (22.1)
≥ 75	92 (14.5)
Male sex, n (%)	319 (50.3)
Immunocompromised patients at high risk of developing COVID-19 complications, n (%)	
≥ 1 high-risk criterion	429 (67.7)
HIV/AIDS	4 (0.6)
Solid tumour	85 (13.4)
Cancer undergoing treatment: radiotherapy	0
Cancer undergoing treatment: radio- or chemotherapy	8 (1.3)

Cancer undergoing treatment: drugs	234 (36.9)
Haematological malignancy	161 (25.4)
Solid organ or haematopoietic stem cell transplantation	121 (19.1)
Primary immune deficiency	188 (29.7)
Immunosuppressive drugs	120 (18.9)
Sickle cell anaemia	3 (0.5)
Major thalassaemia	0
Asplenia	0
Other risk factors/comorbidities of interest, n (%)	
≥1 other comorbidity of interest	364 (57.4)
Age ≥65 years	232 (36.6)
Obesity with BMI ≥30 kg/m ²	42 (6.6)
Type 1 or type 2 diabetes mellitus	78 (12.3)
Chronic lung disease, including asthma	36 (5.7)
Cardiovascular disease, including uncontrolled hypertension	112 (17.7)
Chronic kidney disease (eGFR <30 ml/min), including haemodialysis	67 (10.6)
Chronic liver disease (Child–Pugh B or C)	30 (4.7)
Chronic neurological disease	23 (3.6)

232 AIDS=acquired immunodeficiency syndrome; BMI=body mass index; COVID-19=coronavirus disease 2019;

233 eGFR=estimated glomerular filtration rate; HIV=human immunodeficiency virus

234 **Overall analysis of acute period (29-day) clinical outcomes**

235 ***All-cause clinical outcomes***

236 Among the 634 sotrovimab-treated patients, 82 (12.9%) were hospitalized or died due to any
 237 cause within the 29-day acute period (**Table 3**). Seventy-nine (12.5%) patients were
 238 hospitalized for any cause and seven (1.1%) died due to any cause during the 29-day acute
 239 period. Of the 79 patients who had all-cause hospitalization events, 12 (15.2%) had more
 240 than one hospitalization event during the acute phase. Among hospitalized patients, the
 241 median (IQR) duration of the first all-cause hospitalization was 4.0 (2.0, 9.0) days. Median
 242 (IQR) time to first all-cause hospitalization from the index date was 14.0 (9.5, 22.0) days.
 243 Five (6.3%) of the patients with all-cause hospitalizations were admitted to the intensive care
 244 unit (ICU), with a median (IQR) stay of 6.0 (4.0, 9.0) ICU days. Two patients required
 245 mechanical ventilation and one patient required non-invasive ventilation.

246 ***COVID-19-related clinical outcomes***

247 COVID-19-related hospitalizations during the 29-day acute period were experienced by 2.5%
 248 ($n = 16/634$) of patients (**Table 3**). The median (IQR) duration of stay was 10.0 (6.8, 14.2)
 249 days. Median (IQR) time to hospitalization from the index date was 10.5 (2.2, 20.8) days. Of
 250 patients with COVID-19-related hospitalizations, three (18.8%) were admitted to an ICU, with
 251 a median (IQR) stay of 4.0 (4.0, 6.5) ICU days. One patient required mechanical ventilation.

252 Of the 378 patients treated with sotrovimab at Ghent University Hospital, four (1.1%)
 253 died due to any cause, including one patient who died as a result of COVID-19
 254 complications.

255 **Table 3** Acute period (29-day) all-cause and COVID-19-related outcomes

Outcome	Patients treated with sotrovimab (N = 634)
All-cause hospitalization or death, n (%)	82 (12.9)
All-cause hospitalization, n (%)	79 (12.5)
All-cause hospitalization events, n (%)	
0	555 (87.5)
1	67 (10.6)
2	10 (1.6)
3	2 (0.3)
All-cause deaths, n (%)	7 (1.1)
Number of all-cause hospitalization days	
Mean (SD)	8.3 (12.5)
Median (IQR)	4.0 (7.0)
Time to hospitalization from index date in days	
Mean (SD)	14.9 (7.8)
Median (IQR)	14.0 (12.5)
All-cause ICU admission, n (%)	5 (0.8)
Number of ICU days	
Mean (SD)	7.2 (3.8)
Median (IQR)	6.0 (5.0)
All-cause non-invasive ventilation, n (%)	1 (0.2)
All-cause mechanical ventilation, n (%)	2 (0.3)
COVID-19-related hospitalization, n (%)	16 (2.5)*
Number of COVID-19-related hospitalization days	
Mean (SD)	14.0 (16.3)
Median (IQR)	10.0 (7.5)
Time to COVID-19-related hospitalization from index date in days	11.4 (8.9)

Mean (SD) Median (IQR)	10.5 (18.5)
COVID-19-related ICU admission, <i>n</i> (%)	3 (0.5)
Number of COVID-19-related ICU days Mean (SD) Median (IQR)	5.7 (2.9) 4.0 (2.5)
COVID-19-related non-invasive ventilation, <i>n</i> (%)	0
COVID-19-related mechanical ventilation, <i>n</i> (%)	1 (0.2)

256

257 *Fifteen patients (2.4%) had a first COVID-19-related hospitalization during the 29-day acute period. One patient
258 was hospitalized for the first time during the 29-day acute period for reasons unrelated to COVID-19, but a
259 subsequent hospitalization during the same period was COVID-related. COVID-19=coronavirus disease 2019,
260 ICU=intensive care unit, IQR=interquartile range, SD=standard deviation

261 **Acute period (29-day) clinical outcomes during periods of Delta and Omicron** 262 **predominance**

263 The 29-day acute period all-cause and COVID-19-related outcomes by period of SARS-
264 CoV-2 variant predominance are shown in **Table 4**. The largest number of sotrovimab-
265 treated patients were observed during the BA.1 (34.4%, $n = 218/634$) and BA.2/BA.5
266 codominance (40.2%, $n = 255/634$) periods.

267 During the Delta predominance period, the proportion of sotrovimab-treated patients
268 hospitalized due to any cause was 22.9% ($n = 11/48$). During the Delta/BA.1 codominance,
269 BA.1 predominance, BA.1/BA.2 codominance and BA.2/BA.5 codominance periods, all-
270 cause hospitalizations were experienced by 18.8% ($n = 3/16$), 11.5% ($n = 25/218$), 8.2% ($n =$
271 $8/97$) and 12.5% ($n = 32/255$) of patients, respectively.

272 COVID-19-related hospitalizations were experienced by 6.3% ($n = 3/48$) of
273 sotrovimab-treated patients during the period of Delta predominance, 6.3% ($n = 1/16$) in the
274 Delta/BA.1 codominance period, 1.4% ($n = 3/218$) in the BA.1 predominance period, 2.1% (n
275 $= 2/97$) in the BA.1/BA.2 codominance period and 2.7% ($n = 7/255$) in the BA.2/BA.5
276 codominance period (**Table 4**).

277 No sotrovimab-treated patients died during the Delta predominance period (**Table 4**).
 278 During the Delta/BA.1 codominance period, one sotrovimab-treated patient died ($n = 1/16$).
 279 Two patients died in each of the BA.1 predominance ($n = 2/218$), BA.1/BA.2 codominance (n
 280 $= 2/97$) and BA.2/BA.5 codominance ($n = 2/255$) periods.

281 **Table 4** Acute period (29-day) all-cause and COVID-19-related outcomes by period of
 282 SARS-CoV-2 variant predominance

Outcome	Overall	Delta predominance 04/11/2021– 23/12/2021	Delta/BA.1 codominance 24/12/2021– 01/01/2022	BA.1 predominance 02/01/2022– 09/02/2022	BA.1/BA.2 codominance 10/02/2022– 07/03/2022	BA.2/BA.5 codominance* 08/03/2022– 02/08/2022
Number of patients treated with sotrovimab	634	48	16	218	97	255
Hospitalized due to any cause, n (%)	79 (12.5)	11 (22.9)	3 (18.8)	25 (11.5)	8 (8.2)	32 (12.5)
Hospitalized due to COVID-19, n (%)	16 (2.5)	3 (6.3)	1 (6.3)	3 (1.4)	2 (2.1)	7 (2.7)
Hospitalized due to unknown reason, n (%)	7 (1.1)	0 (0.0)	1 (6.3)	6 (2.8)	0 (0.0)	0 (0.0)
Died due to any cause, n (%)	7 (1.1)	0 (0.0)	1 (6.3)	2 (0.9)	2 (2.1)	2 (0.8)

283
 284 *BA.5 took over from BA.2 as the dominant strain on 25 June 2022. COVID-19=coronavirus disease 2019,
 285 SARS-CoV-2=severe acute respiratory syndrome coronavirus 2

286 **Exploratory analysis of post-acute period (30–90-day) clinical outcomes**

287 In total, 625 patients had follow-up data available for the post-acute period, defined as 30–
 288 90 days after the first sotrovimab administration (index date). Among these patients, 13.8%
 289 ($n = 86/625$) had a new hospitalization event (any cause), 1.6% ($n = 10/625$) had a COVID-

290 19-related hospitalization and 1.1% ($n = 7/625$) died due to any cause during the post-acute
291 period.

292 At Ghent University Hospital, 30–90-day follow-up data were available for 374
293 patients. Among these patients, five died (1.3%), with two deaths due to COVID-19-related
294 reasons.

295 **Discussion**

296 This single-arm, retrospective study describes the real-world clinical outcomes of patients
297 with COVID-19 who received sotrovimab treatment across nine hospitals in Belgium
298 between 1 November 2021 and 31 August 2022. Over two-thirds (67.7%) of the patients in
299 this study had at least one immunocompromising condition, with over one-third of patients
300 (36.9%) receiving chemotherapy for an underlying malignancy. Other commonly reported
301 risk factors for progression to severe COVID-19 were age ≥ 65 years old, cardiovascular
302 diseases (including uncontrolled hypertension), diabetes and CKD. Comparatively, national
303 hospital surveillance, conducted by Sciensano, identified hypertension, cardiovascular
304 disease and diabetes as the top three most frequently reported comorbidities among
305 patients with COVID-19 hospitalized in Belgium over the course of the pandemic [29].

306 During this study, 12.9% of patients ($n = 82/634$) treated with sotrovimab were
307 hospitalized or died due to any cause during the 29-day acute period. This rate is relatively
308 high compared with rates reported in other retrospective or observational studies (all-cause
309 hospitalization and/or mortality ranged from 2.1% to 2.7% during the BA.1 predominance
310 period and from 1.7% to 2.0% during the BA.2 predominance period in a recent systematic
311 literature review reporting on the real-world effectiveness of sotrovimab [30]), but this may be
312 potentially explained by several observations. Firstly, high proportions of all-cause and
313 COVID-19-related hospitalizations were mainly observed among sotrovimab-treated patients
314 during the Delta predominance period (4 November to 23 December 2021) in Belgium.

315 These observations align with nationally reported records of high rates of COVID-19-related
316 hospitalization (12,588 admissions) and deaths (1935) during the Delta predominance period
317 [3, 31] and may reflect the higher disease severity, higher prevalence and more rigorous
318 public health measures associated with the Delta variant relative to subsequent Omicron
319 variants, as well as lower immunity within the population [32, 33]. Additionally, the present
320 study period spanned four SARS-CoV-2 variants (Delta, BA.1, BA.2 and BA.5) compared
321 with one to two variants (primarily BA.1 or BA.2) in other studies [34-36]. Furthermore, the
322 current study had a relatively high proportion of patients with at least one
323 immunocompromising condition (67.7%) compared with other studies [34, 35, 37, 38]. This
324 higher proportion of high-risk patients, necessitating regular inpatient treatment for their
325 underlying conditions, may explain the relatively higher rate of all-cause hospitalization or
326 mortality observed in this current study compared with other real-world studies [30, 34, 35,
327 39].

328 In a recent Danish cohort study, 83% of 2933 sotrovimab-treated patients belonged
329 to very-high-risk groups that included haematological malignancy, solid organ
330 transplantation, and treatment with anti-CD20 for non-malignant haematological diseases
331 within the previous year. Within 90 days of sotrovimab treatment (696 person-years), 30.2%
332 of patients were hospitalized and 5.3% had died due to any cause. The highest prognostic
333 factor was haematological malignancy, followed by age ≥ 65 years [40]. Comparatively, in our
334 study, 68% of patients had at least one immunocompromising condition. A quarter (25.4%)
335 of patients had a haematological malignancy and 36.6% were aged ≥ 65 years; our 30–90-
336 day results show that 13.8% of patients had a new hospitalization event (any cause), and
337 1.1% died due to any cause. Similar to our findings, the Danish study found a higher
338 proportion of hospitalization and death associated with the Delta variant, but no major differences
339 in these outcomes were observed between the Omicron BA.1 and BA.2 variants [40].

340 In our study population, the proportion of sotrovimab-treated patients experiencing
341 COVID-19-related hospitalization was highest during the Delta predominance and

342 Delta/BA.1 codominance (both 6.3%) periods. During the BA.1 predominance, BA.1/BA.2
343 codominance and BA.2/BA.5 codominance periods, COVID-19-related hospitalizations were
344 consistently low (all $\leq 2.7\%$). The median duration of hospitalization in our study (10.0 days)
345 was higher than the national reported figure for Belgium, of 2 days, during the Omicron
346 predominance period [41]; however, the median duration of ICU stays (4.0 days) was the
347 same as the national median duration reported for Belgium [41]. It should be noted that the
348 number of patients admitted to an ICU was low ($n = 3$), which limits interpretation.

349 This study has several potential limitations that should be considered. Firstly, this
350 descriptive, single-arm study did not include a comparator arm, such as patients with similar
351 risk profiles who did not receive sotrovimab after SARS-CoV-2 infection. We were not able to
352 derive a control group due to a lack of similarly high-risk patients who had not received
353 sotrovimab treatment and because patients who did not receive sotrovimab and were not
354 hospitalized were not accounted for in the data used in this study. As a result, it is difficult to
355 infer an association between sotrovimab treatment and clinical outcomes from these data
356 alone. Due to the retrospective, observational study design, variables such as vaccination
357 status and disease severity at enrolment could not be extracted, as these were not
358 structurally reported and standardized in all hospitals. However, vaccination rates in Belgium
359 had reached 73% by the start of this study [42] (and were presumably higher in high-risk
360 groups similar to this study population). Furthermore, one might assume a high vaccination
361 uptake in this population, with patients having received regular follow-up at their treating
362 hospital and being eligible for early treatment with mAbs. Patients who received sotrovimab
363 as an inpatient were excluded from the study, with the exception of patients who were
364 discharged the day after sotrovimab administration. This comprised a large proportion of the
365 total number of patients identified (48.5% [$n = 598/1232$], potentially inducing selection bias
366 in the analyses and limiting the generalizability of the findings. In addition, patients who
367 received sotrovimab in one of the selected hospitals but were later admitted to a different
368 hospital where they progressed to severe disease may not have been captured in our study

369 given its retrospective nature. However, as sotrovimab is expected to be primarily used in
370 patients at risk of progressing to severe outcomes, such as those who are
371 immunocompromised, these patients were likely associated with a reference hospital given
372 their need for frequent medical care; therefore, missing data for clinical outcomes were likely
373 to be low. Similarly, data on the uptake of immunosuppressant drugs and diagnosis of
374 comorbidities were only extractable for patients who were treated or diagnosed in the same
375 hospital where they received their sotrovimab treatment. Information on drugs received in
376 another hospital or prescribed in primary care were not available. Therefore, the number of
377 patients who were at high risk of developing severe COVID-19 disease may have been
378 underestimated. Lastly, as variant sequencing was not routinely undertaken, the specific
379 SARS-CoV-2 variant with which patients were infected could not be determined. Instead, an
380 ecological design was proposed that used the periods of Delta, BA.1, BA.2 and BA.5
381 subvariant predominance and codominance as a proxy for the infecting variant. National
382 genomic surveillance data were used to stratify the study periods into circulating variant
383 predominance periods [28].

384 **Conclusions**

385 This observational study demonstrated consistently low rates of COVID-19-related
386 hospitalizations and all-cause deaths in sotrovimab-treated patients during the Omicron
387 subvariant predominance periods in Belgium, despite the reported decrease in *in vitro*
388 neutralization activity of sotrovimab against BA.2 and BA.5, and over two-thirds of the study
389 population being immunocompromised. Comparative effectiveness studies are warranted to
390 confirm the effectiveness of sotrovimab in highly immunocompromised patients with COVID-
391 19.

392 **List of abbreviations**

393 ATC Anatomical Therapeutic Chemical
394 CKD chronic kidney disease

395	COVID-19	coronavirus disease 2019
396	EMA	European Medicines Agency
397	ICD-10	International Classification of Disease version 10
398	ICU	intensive care unit
399	IQR	interquartile range
400	mAb	monoclonal antibody
401	SARS-CoV-2	severe acute respiratory syndrome coronavirus 2
402	SD	standard deviation

403 **Declarations**

404 **Acknowledgements**

405 The authors wish to thank the Ghent University Hospital Data Science Institute for its support
406 and role in this study.

407 Editorial support (in the form of writing assistance, including preparation of the draft
408 manuscript under the direction and guidance of the authors, collating and incorporating
409 authors' comments for each draft, assembling tables, grammatical editing and referencing)
410 was provided by Kathryn Wardle and Tony Reardon of Apollo, OPEN Health
411 Communications, in accordance with Good Publication Practice guidelines
412 (www.ismpp.org/gpp-2022). The support was funded by GSK and Vir Biotechnology, Inc.

413 **Authors' contributions**

414 Conception: MD, VP, DCG, EJJ, JH, LL

415 Study design: MD, VP, DCG, EJJ, JH, LL, TH, KC, EVB

416 Execution: MD, VP, DCG, EJJ, JH, LL, TH, KC, EVB, MS

417 Acquisition of data: TH, KC, EVB

418 Analysis and interpretation: MD, VP, DCG, EJJ, JH, LL, TH, KC, EVB, MS

419 All authors took part in drafting, revising or critically reviewing the manuscript; gave final
420 approval of the version to be published; have agreed on the journal to which the article has
421 been submitted; and agree to be accountable for all aspects of the work.

422 **Funding**

423 This study was funded by GSK and Vir Biotechnology, Inc. (study number 214878).

424 **Availability of data and materials**

425 The datasets used and/or analysed during the current study are not available due to data
426 privacy.

427 **Competing interests**

428 MS, VP (at time of study), DCG, MD, DDR and EJJ are employees of, and/or shareholders
429 in, GSK. JH (at time of study) and LL are employees of IQVIA, which received funding from
430 GSK and Vir Biotechnology, Inc. to conduct the study. TH, KC and EVB are employees of
431 Ghent University Hospital, which received funding from GSK and Vir Biotechnology, Inc. to
432 conduct the study. EVB also declares speaker fees paid to her institution from GSK, Gilead
433 and Pfizer.

434 **Ethics approval and consent to participate**

435 This study complies with all applicable laws regarding subject privacy. No direct subject
436 contact or primary collection of individual human subject data occurred. Study results were in
437 tabular form and were aggregate analyses that omit subject identification; therefore,
438 informed consent was not required. Ethics committee approval was obtained from each of
439 the participating centres (CHU Saint-Pierre - Comité local d'éthique hospitalier [n° 007]; CHU
440 Ambroise Paré - Comité d'éthique hospitalier; AZ Damiaan - Ethisch comité [n° 057]; AZ Sint
441 Lucas Gent - Commissie medische ethiek; Hôpital Erasme ULB - Comité d'éthique
442 hospitalo-facultaire; UZ Gent - Commissie voor medische ethiek), with the exception of AZ
443 Maria Middelaers, AZ Groeninge and Jan Yperman. For AZ Maria Middelaers, formal ethics
444 committee approval is not required for retrospective database studies; however, the study
445 was approved by a data protection board that oversees information security, ethical and
446 financial aspects in the context of secondary reuse of health data. For AZ Groeninge and
447 Jan Yperman, formal ethics approval is not required for retrospective studies; however, a
448 data access committee at each centre (with medical legal and ethics committee
449 representation) approved the study.

450 **Consent for publication**

451 Not applicable.

452 **References**

- 453 1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. *Acta Biomed.*
454 2020;91:157-60.
- 455 2. World Health Organization. WHO coronavirus (COVID-19) dashboard.
456 <https://covid19.who.int/>. Accessed 21 September 2023.
- 457 3. Sciensano. Belgium COVID-19 epidemiological situation: hospitalisations.
458 [https://lookerstudio.google.com/embed/u/0/reporting/c14a5cfc-cab7-4812-848c-](https://lookerstudio.google.com/embed/u/0/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/uTSKB)
459 [0369173148ab/page/uTSKB](https://lookerstudio.google.com/embed/u/0/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/uTSKB). Accessed 21 September 2023.
- 460 4. Hoge Gezondheidsraad. Aanbevelingen voor het prioriteren van subgroepen van
461 patiënten jonger dan 65 jaar voor vaccinatie tegen SARS-CoV-2 (fase Ib). HGR NR.
462 9618 [Recommendations for prioritizing subgroups of patients younger than 65 years
463 for vaccination against SARS-COV-2 (phase IB). HGR NR. 9618].
464 [https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/2](https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/20210205_hgr-9618_priorites_vaccination_covid-19_vweb.pdf)
465 [0210205_hgr-9618_priorites_vaccination_covid-19_vweb.pdf](https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/20210205_hgr-9618_priorites_vaccination_covid-19_vweb.pdf). Accessed 21
466 September 2023.
- 467 5. Centers for Disease Control and Prevention. Underlying medical conditions
468 associated with higher risk for severe COVID-19: information for healthcare
469 professionals. [https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html)
470 [care/underlyingconditions.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html). Accessed 21 September 2023.
- 471 6. Sciensano. Belgium COVID-19 epidemiological situation: summary.
472 [https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-](https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/ZwmOB)
473 [0369173148ab/page/ZwmOB](https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/ZwmOB). Accessed 21 September 2023.
- 474 7. Gaudinski MR, Coates EE, Houser KV, Chen GL, Yamshchikov G, Saunders JG, et
475 al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal

- 476 antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults. PLoS Med.
477 2018;15:e1002493.
- 478 8. Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, Chen X, et al. Enhanced neonatal
479 Fc receptor function improves protection against primate SHIV infection. Nature.
480 2014;514:642-5.
- 481 9. Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-
482 neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature.
483 2020;583:290-5.
- 484 10. Cathcart AL, Havenar-Daughton C, Lempp FA, Ma D, Schmid MA, Agostini ML, et al.
485 The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent
486 in vitro and in vivo activity against SARS-CoV-2. bioRxiv.
487 2021;doi.org/10.1101/2021.03.09.434607.
- 488 11. Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Rodrigues Falci D,
489 et al. Effect of sotrovimab on hospitalization or death among high-risk patients with
490 mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327:1236-46.
- 491 12. European Medicines Agency. Xevudy summary of product characteristics
492 [https://www.ema.europa.eu/en/documents/product-information/xevudy-epar-product-](https://www.ema.europa.eu/en/documents/product-information/xevudy-epar-product-information_en.pdf)
493 [information_en.pdf](https://www.ema.europa.eu/en/documents/product-information/xevudy-epar-product-information_en.pdf). Accessed 21 September 2023.
- 494 13. European Commission. Daily News 28 / 07 / 2021. Coronavirus: commission signs
495 contract to procure monoclonal anti-body treatment.
496 https://ec.europa.eu/commission/presscorner/detail/en/mex_21_3942. Accessed 21
497 September 2023.
- 498 14. Arickx F, Blot K, Bottieau E, Callens S, Daems J, Dauby N, et al. Task Force COVID
499 Therapeutics. Advice regarding the purchase of sotrovimab (Xevudy) for the

- 500 treatment of COVID-19 patients in Belgium.
501 [https://kce.fgov.be/sites/default/files/2022-](https://kce.fgov.be/sites/default/files/2022-02/Task_Force_COVID_Therapeutics_20210202_Advice_on_the_purchase_of__sotr)
502 [02/Task_Force_COVID_Therapeutics_20210202_Advice_on_the_purchase_of__sotr](https://kce.fgov.be/sites/default/files/2022-02/Task_Force_COVID_Therapeutics_20210202_Advice_on_the_purchase_of__sotr)
503 [ovimab.pdf](https://kce.fgov.be/sites/default/files/2022-02/Task_Force_COVID_Therapeutics_20210202_Advice_on_the_purchase_of__sotr). Accessed 21 September 2023.
- 504 15. Sciensano. Interim clinical guidance for adults with suspected or confirmed COVID-
505 19 in Belgium; version 26. Accessed 21 September 2023.
- 506 16. European Medicines Agency. Xevudy.
507 <https://www.ema.europa.eu/en/medicines/human/EPAR/xevudy>. Accessed 21
508 September 2023.
- 509 17. Australian Government - Department of Health and Aged Care. TGA provisionally
510 approves GlaxoSmithKline's COVID-19 treatment: sotrovimab (XEVUDY).
511 [https://www.tga.gov.au/news/media-releases/tga-provisionally-approves-](https://www.tga.gov.au/news/media-releases/tga-provisionally-approves-glaxosmithklines-covid-19-treatment-sotrovimab-xevudy)
512 [glaxosmithklines-covid-19-treatment-sotrovimab-xevudy](https://www.tga.gov.au/news/media-releases/tga-provisionally-approves-glaxosmithklines-covid-19-treatment-sotrovimab-xevudy). Accessed 21 September
513 2023.
- 514 18. Medicines & Healthcare products Regulatory Agency. Summary of product
515 characteristics for Xevudy. [https://www.gov.uk/government/publications/regulatory-](https://www.gov.uk/government/publications/regulatory-approval-of-xevudy-sotrovimab/summary-of-product-characteristics-for-xevudy)
516 [approval-of-xevudy-sotrovimab/summary-of-product-characteristics-for-xevudy](https://www.gov.uk/government/publications/regulatory-approval-of-xevudy-sotrovimab/summary-of-product-characteristics-for-xevudy).
517 Accessed 21 September 2023.
- 518 19. GSK. Xevudy (sotrovimab) granted marketing authorisation by the European
519 Commission for the early treatment of COVID-19. [https://www.gsk.com/en-](https://www.gsk.com/en-gb/media/press-releases/xevudy-sotrovimab-granted-marketing-authorisation-by-the-european-commission-for-the-early-treatment-of-covid-19/)
520 [gb/media/press-releases/xevudy-sotrovimab-granted-marketing-authorisation-by-the-](https://www.gsk.com/en-gb/media/press-releases/xevudy-sotrovimab-granted-marketing-authorisation-by-the-european-commission-for-the-early-treatment-of-covid-19/)
521 [european-commission-for-the-early-treatment-of-covid-19/](https://www.gsk.com/en-gb/media/press-releases/xevudy-sotrovimab-granted-marketing-authorisation-by-the-european-commission-for-the-early-treatment-of-covid-19/). Accessed 21 September
522 2023.
- 523 20. GSK. GSK received approval for monoclonal antibody, “XEVUDY for intravenous
524 injection” (generic name: sotrovimab), for the treatment of COVID-19.

- 525 https://jp.gsk.com/media/7512/20210927_xevudy-approval-e.pdf. Accessed 21
526 September 2023.
- 527 21. Mendiola-Pastrana IR, López-Ortiz E, Río de la Loza-Zamora JG, González J,
528 Gómez-García A, López-Ortiz G. SARS-CoV-2 variants and clinical outcomes: a
529 systematic review. *Life (Basel)*. 2022;12:170.
- 530 22. World Health Organization. Coronavirus disease (COVID-19) pandemic.
531 <https://www.who.int/europe/emergencies/situations/covid-19>. Accessed 21
532 September 2023.
- 533 23. Superior Health Council. COVID-19 vaccination: autumn / winter season 2022 –
534 2023. SHC № 9721.
535 [https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/2](https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/20220706_shc-9721_covid-19_booster_autumn-winter_2022-2023_vweb.pdf)
536 [0220706_shc-9721_covid-19_booster_autumn-winter_2022-2023_vweb.pdf](https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/20220706_shc-9721_covid-19_booster_autumn-winter_2022-2023_vweb.pdf).
537 Accessed 21 September 2023.
- 538 24. Park YJ, Pinto D, Walls AC, Liu Z, De Marco A, Benigni F, et al. Imprinted antibody
539 responses against SARS-CoV-2 Omicron sublineages. *Science*. 2022;378:619-27.
- 540 25. Jonckheer P, Jaspers V, Costa E, Castanares-Zapatero D, Roberfroid D, Hulstaert F.
541 Task Force COVID Therapeutics. Home-based medication management for non-
542 severe SARS-CoV-2 infection. [https://kce.fgov.be/sites/default/files/2022-](https://kce.fgov.be/sites/default/files/2022-05/COVID19_Therapeutics_for_GPs_NoteKCE_06052022.pdf)
543 [05/COVID19_Therapeutics_for_GPs_NoteKCE_06052022.pdf](https://kce.fgov.be/sites/default/files/2022-05/COVID19_Therapeutics_for_GPs_NoteKCE_06052022.pdf). Accessed 21
544 September 2023.
- 545 26. Case JB, Mackin S, Errico JM, Chong Z, Madden EA, Whitener B, et al. Resilience of
546 S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-
547 2 Omicron lineage strains. *Nat Commun*. 2022;13:3824.

- 548 27. Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, et al. Characterization and
549 antiviral susceptibility of SARS-CoV-2 Omicron BA.2. *Nature*. 2022;607:119-27.
- 550 28. Sciensano. Belgium COVID-19 epidemiological situation: variants.
551 [https://lookerstudio.google.com/embed/u/0/reporting/c14a5cfc-cab7-4812-848c-](https://lookerstudio.google.com/embed/u/0/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/urrUC)
552 [0369173148ab/page/urrUC](https://lookerstudio.google.com/embed/u/0/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/urrUC). Accessed 21 September 2023.
- 553 29. Sciensano. Belgium COVID-19 epidemiological situation: hospitalisations - clinical
554 surveillance. [https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-](https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/JL1qB)
555 [848c-0369173148ab/page/JL1qB](https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/JL1qB). Accessed 21 September 2023.
- 556 30. Drysdale M, Gibbons DC, Singh M, Rolland C, Lavoie L, Skingsley A, et al. Real-
557 world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during
558 Omicron BA.2 subvariant predominance: a systematic literature review. *medRxiv*.
559 2023;doi.org/10.1101/2023.03.09.23287034.
- 560 31. Sciensano. Belgium COVID-19 epidemiological situation: deaths.
561 [https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-](https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/QTSKB)
562 [0369173148ab/page/QTSKB](https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/QTSKB). Accessed 21 September 2023.
- 563 32. Wang C, Liu B, Zhang S, Huang N, Zhao T, Lu QB, et al. Differences in incidence
564 and fatality of COVID-19 by SARS-CoV-2 Omicron variant versus Delta variant in
565 relation to vaccine coverage: a world-wide review. *J Med Virol*. 2023;95:e28118.
- 566 33. Sigal A, Milo R, Jassat W. Estimating disease severity of Omicron and Delta SARS-
567 CoV-2 infections. *Nat Rev Immunol*. 2022;22:267-9.
- 568 34. Cheng MM, Reyes C, Satram S, Birch H, Gibbons DC, Drysdale M, et al. Real-world
569 effectiveness of sotrovimab for the early treatment of COVID-19 during SARS-CoV-2
570 Delta and Omicron waves in the USA. *Infect Dis Ther*. 2023;12:607-21.

- 571 35. Zheng B, Green ACA, Tazare J, Curtis HJ, Fisher L, Nab L, et al. Comparative
572 effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19
573 outcomes in patients in the community: observational cohort study with the
574 OpenSAFELY platform. *BMJ*. 2022;379:e071932.
- 575 36. Harman K, Nash SG, Webster HH, Groves N, Hardstaff J, Bridgen J, et al.
576 Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases
577 treated with sotrovimab in the community in England. *Influenza Other Respir Viruses*.
578 2023;17:e13150.
- 579 37. Razonable RR, Tulledge-Scheitel SM, Hanson SN, Arndt RF, Speicher LL, Seville
580 TA, et al. Real-world clinical outcomes of bebtelovimab and sotrovimab treatment of
581 high-risk persons with coronavirus disease 2019 during the Omicron epoch. *Open
582 Forum Infect Dis*. 2022;9:ofac411.
- 583 38. Evans A, Qi C, Adebayo JO, Underwood J, Coulson J, Bailey R, et al. Real-world
584 effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing
585 hospital admission among higher-risk patients with COVID-19 in Wales: a
586 retrospective cohort study. *J Infect*. 2023;86:352-60.
- 587 39. Patel V, Yarwood MJ, Levick B, Gibbons DC, Drysdale M, Kerr W, et al.
588 Characteristics and outcomes of patients with COVID-19 at high-risk of disease
589 progression receiving sotrovimab, oral antivirals or no treatment in England.
590 *medRxiv*. 2022;doi.org/10.1101/2022.11.28.22282808.
- 591 40. Rasmussen LD, Lebech AM, Øvrehus A, Poulsen BK, Christensen HR, Nielsen H, et
592 al. Experience with sotrovimab treatment of SARS-CoV-2-infected patients in
593 Denmark. *Br J Clin Pharmacol*. 2023;89:1820-33.
- 594 41. De Mot L, Robalo Q, Dockx Y, Vandromme M, De Pauw R, Serrien B, et al. COVID-
595 19 clinical hospital surveillance report. [https://covid-](https://covid-19clinicalhospitalreport.be/)

596 19.sciensano.be/sites/default/files/Covid19/COVID-
597 19_Hospital_epidemiology_Part_1.pdf. Accessed 21 September 2023.
598 42. Sciensano. Belgium COVID-19 epidemiological situation: vaccination.
599 [https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-](https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/p_j1f02pfnpc)
600 [0369173148ab/page/p_j1f02pfnpc](https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/p_j1f02pfnpc). Accessed 21 September 2023.

601

602 **Additional files**

603 Additional file 1 (PDF) - Supplementary Appendix, containing ATC and ICD-10 codes used in
604 this study, and all-cause and COVID-19-related outcomes by study month

605

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Fig. 1 Proportion of SARS-CoV-2 variants over time in Belgium [28]. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2